Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

Recent & Breaking News (GREY:COTQF)

IIROC Trading Halt - COT

Canada NewsWire October 15, 2020

IIROC Trading Resumption - COT

Canada NewsWire November 7, 2019

IIROC Trading Halt - COT

Canada NewsWire October 7, 2019

Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

GlobeNewswire July 18, 2019

Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

GlobeNewswire June 27, 2019

Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

GlobeNewswire June 5, 2019

Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering

GlobeNewswire June 4, 2019

Cotinga Pharmacueticals Announces Closing of Unit Offering

GlobeNewswire May 22, 2019

Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

GlobeNewswire May 8, 2019

Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results

GlobeNewswire April 5, 2019

Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering

GlobeNewswire March 19, 2019

Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

GlobeNewswire February 26, 2019

Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2

GlobeNewswire January 29, 2019

Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2

GlobeNewswire January 15, 2019

Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2

GlobeNewswire January 8, 2019

Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results

GlobeNewswire January 3, 2019

Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2

GlobeNewswire November 5, 2018

Cotinga Pharmaceuticals Reports Fiscal 2019 First Quarter Financial and Operating Results

GlobeNewswire October 2, 2018

Cotinga Pharmaceuticals Announces Presentation on COTI-2 at 11th International Symposium on Translational Research in Oncology

GlobeNewswire September 19, 2018

Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results

GlobeNewswire August 29, 2018